These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21486874)

  • 21. History of Orphan Drug Regulation-United States and Beyond.
    Haffner ME
    Clin Pharmacol Ther; 2016 Oct; 100(4):342-3. PubMed ID: 27392514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health policy, disparities, and the kidney.
    Williams AW
    Adv Chronic Kidney Dis; 2015 Jan; 22(1):54-9. PubMed ID: 25573513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. R&D policy, agency costs and innovation in personalized medicine.
    Yin W
    J Health Econ; 2009 Sep; 28(5):950-62. PubMed ID: 19671480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drugs for rare disorders.
    Cremers S; Aronson JK
    Br J Clin Pharmacol; 2017 Aug; 83(8):1607-1613. PubMed ID: 28653488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Orphan drugs for rare diseases: is it time to revisit their special market access status?
    Simoens S; Cassiman D; Dooms M; Picavet E
    Drugs; 2012 Jul; 72(11):1437-43. PubMed ID: 22747423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improved Diagnosis and Care for Rare Diseases through Implementation of Precision Public Health Framework.
    Baynam G; Bowman F; Lister K; Walker CE; Pachter N; Goldblatt J; Boycott KM; Gahl WA; Kosaki K; Adachi T; Ishii K; Mahede T; McKenzie F; Townshend S; Slee J; Kiraly-Borri C; Vasudevan A; Hawkins A; Broley S; Schofield L; Verhoef H; Groza T; Zankl A; Robinson PN; Haendel M; Brudno M; Mattick JS; Dinger ME; Roscioli T; Cowley MJ; Olry A; Hanauer M; Alkuraya FS; Taruscio D; Posada de la Paz M; Lochmüller H; Bushby K; Thompson R; Hedley V; Lasko P; Mina K; Beilby J; Tifft C; Davis M; Laing NG; Julkowska D; Le Cam Y; Terry SF; Kaufmann P; Eerola I; Norstedt I; Rath A; Suematsu M; Groft SC; Austin CP; Draghia-Akli R; Weeramanthri TS; Molster C; Dawkins HJS
    Adv Exp Med Biol; 2017; 1031():55-94. PubMed ID: 29214566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rare diseases: what's next?
    Remuzzi G; Garattini S
    Lancet; 2008 Jun; 371(9629):1978-9. PubMed ID: 18555899
    [No Abstract]   [Full Text] [Related]  

  • 28. Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy.
    Clarke JT
    CMAJ; 2006 Jan; 174(2):189-90. PubMed ID: 16415465
    [No Abstract]   [Full Text] [Related]  

  • 29. The burden of rare diseases.
    Ferreira CR
    Am J Med Genet A; 2019 Jun; 179(6):885-892. PubMed ID: 30883013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The intersection of disability and healthcare disparities: a conceptual framework.
    Meade MA; Mahmoudi E; Lee SY
    Disabil Rehabil; 2015; 37(7):632-41. PubMed ID: 25060038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rare diseases are a 'common' problem for clinicians.
    Elliott E; Zurynski Y
    Aust Fam Physician; 2015 Sep; 44(9):630-3. PubMed ID: 26488039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rare diseases, orphan drugs and their regulation: questions and misconceptions.
    Tambuyzer E
    Nat Rev Drug Discov; 2010 Dec; 9(12):921-9. PubMed ID: 21060315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Orphan Drug Act and the development of stem cell-based products for rare diseases.
    Freeman SN; Burke KA; Imoisili MA; Coté TR
    Cell Stem Cell; 2010 Sep; 7(3):283-7. PubMed ID: 20804965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Delayed access to treatments for rare diseases: who's to blame?
    Feltmate K; Janiszewski PM; Gingerich S; Cloutier M
    Respirology; 2015 Apr; 20(3):361-9. PubMed ID: 25722183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Orphan Drug Act: Restoring the Mission to Rare Diseases.
    Daniel MG; Pawlik TM; Fader AN; Esnaola NF; Makary MA
    Am J Clin Oncol; 2016 Apr; 39(2):210-3. PubMed ID: 26580246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exclusion of orphan drugs for certain covered entities under 340B Program. Final rule.
    Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS)
    Fed Regist; 2013 Jul; 78(141):44016-28. PubMed ID: 23882725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developing treatments for inborn errors: incentives available to the clinician.
    Haffner ME
    Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
    Burke KA; Freeman SN; Imoisili MA; Coté TR
    Clin Pharmacol Ther; 2010 Oct; 88(4):449-53. PubMed ID: 20856241
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.